Drugs / Budoprutug
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07090655 | Aug 2025 → Apr 2026 overdue | — | Climb Bio, Inc. | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07011043 | Jul 2025 → Apr 2027 expected | systemic lupus erythematosus | Climb Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07564596 | Jun 2026 → Sep 2027 expected | systemic lupus erythematosus | Climb Bio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07043946 | Jun 2025 → Aug 2027 expected | autoimmune thrombocytopenia | Climb Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06570434 | Jan 2025 → Dec 2026 | systemic lupus erythematosus | Tenet Medicines | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04652570 | May 2021 → Nov 2023 | membranous glomerulonephritis | Tenet Medicines | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07096843 | Aug 2025 → Oct 2027 expected | membranous glomerulonephritis | Climb Bio, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05441826 | May 2022 → May 2023 | focal segmental glomerulosclerosis, minimal change disease | Tenet Medicines | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Climb Bio, Inc. | Results Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 climbbio.com ↗
These initial data suggest that targeting CD19 with budoprutug may offer a differentiated approach in ITP, enabling robust B-cell depletion, durable platelet responses, and an acceptable safety and tolerability profile. |
| 2026-04-07 | Climb Bio, Inc. | Regulatory Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy climbbio.com ↗ |
| 2026-01-08 | Climb Bio, Inc. | Regulatory Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 climbbio.com ↗
Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China |
| 2025-10-17 | Climb Bio, Inc. | Results Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 climbbio.com ↗
Long-term follow-up clinical data from the previously conducted Phase 1b trial (NCT04652570) in pMN demonstrated long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. |
| 2024-11-12 | Climb Bio, Inc. | Regulatory Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights climbbio.com ↗
The U.S. Food and Drug Administration (FDA) has cleared the IND allowing Climb Bio to initiate a Phase 1b open label |
All press releases naming this drug 7 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | budoprutug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06570434 ↗ |
| Known as | TNT119 | “A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical...” NCT07043946 ↗ |
| Known as | VB119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05441826 ↗ |
| Action | Deplete | “projected to deplete targeted cells” NCT07011043 ↗ |
| Modality | Monoclonal antibody | “Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb)” NCT05441826 ↗ |
| Route | Intravenous | “administered as intravenous infusion” NCT04652570 ↗ |
| Target | CD19 | “selectively binds to CD19” NCT07011043 ↗ |